SCHEMBL3493445

SCHEMBL3493445

Cc1cc(C(=O)N2CCN(C(=O)O)C[C@H]2C(O)CC(N)=O)c(-c2ccccc2)n1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.39
RAB9A P51151 5/20 0.36
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 3/20 0.36
MAPT P10636 3/20 0.36
NOTUM Q6P988 2/20 0.36
CNR2 P34972 7/20 0.35
CNR1 P21554 6/20 0.35
LMNA P02545 3/20 0.34
TP53 P04637 2/20 0.34
HPGD P15428 2/20 0.32
HTT P42858 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13341048 0.89 SMN1; SMN2 (0.37) SMN1; SMN2MAPTTP53
SCHEMBL3492458 0.89 LMNA (0.36) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3492878 0.88 ALDH1A1 (0.37) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3493147 0.87 SMN1; SMN2 (0.34) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3491489 0.87 SMN1; SMN2 (0.34) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3496494 0.85 CNR2 (0.39) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3491571 0.85 CNR2 (0.39) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3491575 0.85 CNR2 (0.39) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3493410 0.84 ALDH1A1 (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPT
SCHEMBL3493406 0.84 ALDH1A1 (0.38) SMN1; SMN2RAB9AALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
EP-1984355-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION Takeda Pharmaceutical Company Limited (JP) 2008-10-29 EP disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 SMN1; SMN2 4730/4885RAB9A 656/4885ALDH1A1 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.